Chimeric Mouse Model for Human Sickle Cell Disease Erythropoiesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mouse models for studying Sickle Cell Disease (SCD) are inadequate as they exclusively contain mouse red cells, failing to capture the heterogeneity encountered in patients and requiring careful interpretation of findings, especially regarding genetic modifications and therapeutics.
Innovation Solution
Development of genetically modified non-human animals, such as mice, that express human M-CSF, IL-3, GM-CSF, SIRPA, and TPO, with specific mutations like cKitw41 or Fah deficiency, allowing for engraftment with human hematopoietic cells and supporting human erythropoiesis, thereby mimicking human SCD more accurately.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If mouse models are used to study Sickle Cell Disease, then the model is simple and easy to maintain, but the model fails to capture human disease heterogeneity and requires careful interpretation of findings
Solution Approach 1:
The patent implements a nested doll approach by engrafting human hematopoietic stem and progenitor cells into immunodeficient mouse models. The human cells nest within the mouse host, creating a chimeric system where human blood cells are produced in a mouse body. This allows the simple mouse model to harbor complex human disease characteristics, resolving the contradiction between model simplicity and disease accuracy.
Solution Approach 2:
The patent uses immunodeficient mouse strains as intermediaries between fully human models and simple mouse models. By selectively removing immune system components (Rag2, Il2rg, C5), the mouse host becomes a permissive environment for human cell engraftment without complete humanization, serving as an intermediary that enables human cell survival while maintaining mouse model simplicity.
2Reliability
If human hematopoietic cells are engrafted into mouse models, then the model accuracy for human SCD is improved, but the engraftment efficiency and human cell survival are reduced due to immune rejection
Solution Approach 1:
The patent applies preliminary action by pre-modifying the mouse host immune system through genetic knockout of immune-related genes (Rag2, Il2rg, C5) before engrafting human cells. This preliminary immunodeficiency preparation creates a permissive environment that prevents immune rejection of human hematopoietic cells, ensuring high engraftment efficiency and long-term human cell survival.
Solution Approach 2:
The patent implements preliminary anti-action by knocking out genes that mediate immune rejection (Rag2 for T/B cell development, Il2rg for gamma chain signaling, C5 for complement-mediated lysis) before human cell engraftment. This preemptive neutralization of immune attack mechanisms protects human cells from rejection, resolving the contradiction between model accuracy and engraftment efficiency.
3Reliability
If multiple human cytokine genes are introduced to support human erythropoiesis, then the support for human red blood cell production is improved, but the genetic modification complexity increases
Solution Approach 1:
The patent implements multi-functionality by introducing a panel of human cytokine genes (M-CSF, IL-3, GM-CSF, TPO, SIRPA) that collectively support multiple aspects of human hematopoiesis. Each cytokine targets different cell lineages and developmental stages, creating a comprehensive support system that addresses the complex requirements of human blood cell production within the mouse host environment.
Solution Approach 2:
The patent merges multiple human cytokine expression systems into a coordinated network within the mouse host. By simultaneously expressing several human cytokines that work synergistically (M-CSF for macrophages, IL-3 for multilineage, GM-CSF for myeloid, TPO for megakaryocytes), the patent creates an integrated human-like hematopoietic microenvironment, resolving the contradiction between comprehensive support and modification complexity through functional integration.
Data Source
AI summary
The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use,